Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 12, 2009, Pages 1291-1298

  Kim, J H ^a   Yoon, H K ^a   Kim, S Y ^a   Kim, K M ^a   Ko, G Y ^a   Gwon, D I ^a   Sung, K B ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; FEMALE; FOLLOW UP; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PORTAL VEIN; STATISTICS; SURVIVAL; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 77449096379     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04016.x     Document Type: Article

References (29)

1. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9. (Pubitemid 44142456)
2. Liovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734-9. (Pubitemid 34607087)
3. Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 2007; 18: 1517-27.
4. Shen H, Agarwal D, Qi R, et al. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther 2007; 26: 393-400. (Pubitemid 47063156)
5. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-a for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-91.
6. Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006; 17: 225-32.
7. Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008; 113: 1614-22.
8. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007; 25: 978-86. (Pubitemid 350002864)
9. Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198: 33-40.
10. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999; 28: 334-40. (Pubitemid 29246409)
11. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994; 19: 1115-23.
12. Wallace MJ, Ahrar K, Madoff DC. Chemoembolization of the liver after portal vein embolization: report of three cases. J Vasc Interv Radiol 2008; 19: 1513-7.
13. Kiely JM, Rilling WS, Touzios JG, et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 2006; 17: 47-53. (Pubitemid 44392032)
14. Georgiades CS, Hong K, D'Angelo M, Geschwind JFH. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-9. (Pubitemid 44431162)
15. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
16. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81. (Pubitemid 28466823)
17. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. Am J Roentgenol 1995; 165: 315-21.
18. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas: a univariate and multivariate analysis. Cancer 1990; 65: 1104-10. (Pubitemid 20072042)
19. Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001; 16: 660-5. (Pubitemid 34188841)
20. Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008; 19: 862-9.
21. Kawai S, Tani M, Okamura J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1994; 33(Suppl.): S97-102. (Pubitemid 24147975)
22. Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of lipiodoltranscatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997; 24 (Suppl. 6):S6-38-45. (Pubitemid 27209105)
23. Izaki K, Sugimoto K, Sugimura K, Hirota S. Transcatheter arterial embolization for advanced tumor thrombus with marked arterioportal or arteriovenous shunt complicating hepatocellular carcinoma. Radiat Med 2004; 22: 155-62. (Pubitemid 38980993)
24. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7. (Pubitemid 29023987)
25. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71. (Pubitemid 34454013)
26. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
27. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35. (Pubitemid 40613379)
28. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolizationbased therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004; 15: 439-52. (Pubitemid 38736941)
29. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-95. (Pubitemid 34810185)